- Home
- IHS vs BEAM Comparison
IHS vs BEAM Comparison
Compare IHS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- BEAM
- Stock Information
- Founded
- IHS 2001
- BEAM 2017
- Country
- IHS United Kingdom
- BEAM United States
- Employees
- IHS N/A
- BEAM N/A
- Industry
- IHS Telecommunications Equipment
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHS Telecommunications
- BEAM Health Care
- Exchange
- IHS Nasdaq
- BEAM Nasdaq
- Market Cap
- IHS 2.3B
- BEAM 2.3B
- IPO Year
- IHS 2021
- BEAM 2020
- Fundamental
- Price
- IHS $6.36
- BEAM $22.11
- Analyst Decision
- IHS Buy
- BEAM Strong Buy
- Analyst Count
- IHS 7
- BEAM 11
- Target Price
- IHS $8.89
- BEAM $49.40
- AVG Volume (30 Days)
- IHS 573.3K
- BEAM 2.3M
- Earning Date
- IHS 11-12-2025
- BEAM 11-04-2025
- Dividend Yield
- IHS N/A
- BEAM N/A
- EPS Growth
- IHS N/A
- BEAM N/A
- EPS
- IHS 1.37
- BEAM N/A
- Revenue
- IHS $1,765,825,000.00
- BEAM $55,701,000.00
- Revenue This Year
- IHS $2.15
- BEAM N/A
- Revenue Next Year
- IHS $5.32
- BEAM $19.01
- P/E Ratio
- IHS $4.64
- BEAM N/A
- Revenue Growth
- IHS N/A
- BEAM N/A
- 52 Week Low
- IHS $2.61
- BEAM $13.53
- 52 Week High
- IHS $8.00
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- IHS 43.24
- BEAM 41.29
- Support Level
- IHS $5.71
- BEAM $20.76
- Resistance Level
- IHS $8.00
- BEAM $22.72
- Average True Range (ATR)
- IHS 0.38
- BEAM 1.67
- MACD
- IHS -0.04
- BEAM -0.28
- Stochastic Oscillator
- IHS 27.73
- BEAM 23.66
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.